Fig. 2: Clinical activity of locoregionally delivered IL-13Rα2-CAR-T cells.

a, Swimmer plot of evaluable patients and their clinical outcomes. WHO grade is at time of treatment. Tumor IDH mutations are indicated by yes (Y) or no (N); ND, not determined; DS, dose schedule. Black lines indicate CAR-T cell cycles administered to route dictated by arm (arm 1: ICT-Biopsy; arm 2: ICT-Resection; arm 3: ICV; arms 4 and 5: dual ICT/ICV). White lines indicate additional CAR-T cell cycles administered ICV. Yellow lines indicate additional CAR-T cell cycles administered ICT. Bold UPN numbers, evaluable rGBM patients (n = 42, evaluable for survival n = 41); #, diffuse midline glioma, H3 K27-altered. b, OS of evaluable rGBM patients from date of surgery. Thin lines denote 95% CIs; dashed line depicts median in months (Mo). Median survival with 95% CI in parentheses also indicated. c, Survival comparison of evaluable rGBM patients who were infused with either Tcm- or Tn/mem-derived cell products. Dashed lines depict medians in Mo. Median survival times with 95% CIs in parentheses also indicated; NA means infinity. P value for survival comparison was determined using the log-rank test. Red dots indicate censored participants (that is, lost to follow-up but had not passed away).